Completed PHASE1 INTERVENTIONAL 1-arm NCT01562886

The Rilpivirine Cerebrospinal-fluid (CSF) Study

A Phase I Pharmacokinetic Study to Assess the Cerebrospinal-fluid (CSF) Exposure of Rilpivirine in HIV-infected Subjects Switching From TDF/FTC/Nevirapine to TDF/FTC/Rilpivirine

Sponsor: Imperial College London

Conditions HIV

Interventions Rilpivirine

Updated 7 times since 2017 Last updated: May 19, 2014 Started: Mar 31, 2012 Primary completion: Nov 30, 2012 Completion: Feb 28, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates HIV and is currently completed. Imperial College London leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Imperial College London
Janssen-Cilag Ltd.

Data source: Imperial College London

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom